

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims**1-32. (Canceled)**

33. **(Currently Amended)** A method of inducing or enhancing a cytotoxic T cell response against β hCG comprising:

~~forming contacting antigen presenting cells (APCs) either in vivo or ex vivo with a composition containing a conjugate of β hCG and a monoclonal antibody which binds to the human macrophage mannose receptor (MMR), wherein the composition does not include an adjuvant or immunostimulatory agent, and contacting the conjugate either in vivo or ex vivo with antigen presenting cells such that β hCG is internalized, processed and presented to T cells in a manner which induces or enhances a cytotoxic T cell response mediated by both CD4⁺ and CD8⁺ T cells against β hCG.~~

34. **(Previously Presented)** The method of claim 33, which further induces or enhances a helper T cell response against β hCG.

35. **(Previously Presented)** The method of claim 33, wherein β hCG presenting cells are dendritic cells.

36. **(Previously Presented)** The method of claim 33, wherein the T cell response is induced through both MHC Class I and MHC Class II pathways.

37-38. (Canceled)

39. **(Original)** The method of claim 33, wherein the antibody is selected from the group consisting of human, humanized and chimeric antibodies.

40. **(Original)** The method of claim 33, wherein the antibody is selected from the group consisting of a whole antibody, an Fab fragment and a single chain antibody.

41. **(Currently Amended)** The method of claim 33, wherein the antibody comprises a heavy chain variable region comprising FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 sequences and a light chain variable region comprising FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 sequences, wherein:

- (a) the heavy chain variable region CDR3 sequence comprises SEQ ID NO: 15; and
- (b) the light chain variable region CDR3 sequence comprises SEQ ID NO: 18;
- (c) the heavy chain variable region CDR2 sequence comprises SEQ ID NO: 14;
- (d) the light chain variable region CDR2 sequence comprises SEQ ID NO: 17;
- (e) the heavy chain variable region CDR1 sequence comprises SEQ ID NO:13; and
- (f) the light chain variable region CDR1 sequence comprises SEQ ID NO: 16.

42-43. **(Canceled)**

44. **(Previously Presented)** The method of claim 41, wherein the antibody comprises heavy chain and light chain variable regions comprising the amino acid sequences shown in SEQ ID NO:4 and SEQ ID NO:8, respectively.

45-47. **(Canceled)**

48. **(Original)** The method of claim 33, wherein the conjugate is administered *in vivo* to a subject.

49. **(Previously Presented)** The method of claim 48, wherein the subject is immunized against β hCG.

50. **(Currently Amended)** A method of inducing or enhancing a T cell-mediated immune response against β hCG, comprising contacting antigen presenting cells (APCs) with a composition containing a molecular conjugate of comprising a monoclonal antibody that binds

to the human macrophage mannose receptor (MMR) linked to β hCG, ~~with antigen presenting cells wherein the composition does not include an adjuvant or immunostimulatory agent~~, such that β hCG is processed and presented to T cells in a manner which induces or enhances a T cell-mediated response mediated by both CD4 $^{+}$ and CD8 $^{+}$ T cells against β hCG.

51. **(Previously Presented)** The method of claim 50, wherein the T cell response is mediated by cytotoxic T cells and/or helper T cells.

52. **(Previously Presented)** The method of claim 50, wherein the T cell response is induced by cross-presentation of β hCG to T cells through both MHC Class I and MHC Class II pathways.

53-54. **(Canceled)**

55. **(Previously Presented)** The method of claim 50, wherein the molecular conjugate is contacted with the dendritic cells *in vivo*.

56. **(Previously Presented)** The method of claim 50, wherein the molecular conjugate is contacted with the dendritic cells *ex vivo*.

57-58. **(Canceled)**

59. **(Currently Amended)** A method of immunizing a subject comprising administering a composition containing a molecular conjugate of ~~e~~ comprising a monoclonal antibody that binds to the human macrophage mannose receptor (MMR) linked to β hCG, wherein the composition does not include an adjuvant or immunostimulatory agent ~~in combination with an adjuvant and a cytokine which stimulates proliferation of dendritic cells or an immunostimulatory agent~~, such that the molecular conjugate induces or enhances a cytotoxic T cell response mediated by both CD4 $^{+}$ and CD8 $^{+}$ T cells against β hCG.